1. Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne
- Author
-
Lourbakos, A., Yau, N., de Bruijn, P., Hiller, M., Kozaczynska, K., Jean-Baptiste, R., Reza, M., Wolterbeek, R., Koeks, Z., Ayoglu, Burcu, de Klerk, D., Campion, G., Zaharieva, I., Nadarajah, V. D., Nilsson, P., Al-Khalili Szigyarto, Cristina, Muntoni, F., Lochmuller, H., Verschuuren, J. J., Goemans, N., Tulinius, M., Niks, E. H., de Kimpe, S., Aartsma-Rus, A., 't Hoen, Peter A. C., Spitali, P., Lourbakos, A., Yau, N., de Bruijn, P., Hiller, M., Kozaczynska, K., Jean-Baptiste, R., Reza, M., Wolterbeek, R., Koeks, Z., Ayoglu, Burcu, de Klerk, D., Campion, G., Zaharieva, I., Nadarajah, V. D., Nilsson, P., Al-Khalili Szigyarto, Cristina, Muntoni, F., Lochmuller, H., Verschuuren, J. J., Goemans, N., Tulinius, M., Niks, E. H., de Kimpe, S., Aartsma-Rus, A., 't Hoen, Peter A. C., and Spitali, P.
- Abstract
Duchenne Muscular Dystrophy (DMD) is a severe muscle disorder caused by lack of dystrophin. Predictive biomarkers able to anticipate response to the therapeutic treatments aiming at dystrophin re-expression are lacking. The objective of this study is to investigate Matrix Metalloproteinase-9 (MMP-9) as predictive biomarker for Duchenne. Two natural history cohorts were studied including 168 longitudinal samples belonging to 66 patients. We further studied 1536 samples obtained from 3 independent clinical trials with drisapersen, an antisense oligonucleotide targeting exon 51: an open label study including 12 patients; a phase 3 randomized, double blind, placebo controlled study involving 186 patients; an open label extension study performed after the phase 3. Analysis of natural history cohorts showed elevated MMP-9 levels in patients and a significant increase over time in longitudinal samples. MMP-9 decreased in parallel to clinical stabilization in the 12 patients involved in the open label study. The phase 3 study and subsequent extension study clarified that the decrease in MMP-9 levels was not predictive of treatment response. These data do not support the inclusion of serum MMP-9 as predictive biomarker for DMD patients., QC 20180111
- Published
- 2017
- Full Text
- View/download PDF